Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2010 consensus guidelines for definitive external beam radiotherapy for prostate carcinoma

Journal of Medical Imaging and Radiation Oncology

Volumn 54, Issue 6, 2010, Pages 513-525

  Hayden, A J ^a   Martin, J M ^d   Kneebone, A B ^b   Lehman, M ^e   Wiltshire, K L ^h   Skala, M ⁱ   Christie, D ^g   Vial, P ^c   McDowall, R ^f   Tai, K H ^h  

^a Westmead Cancer Care Centre   (Australia)

^b SYDNEY CANCER CENTRE   (Australia)

^c Liverpool and Macarthur Cancer Therapy Centres   (Australia)

^d Radiation Oncology Queensland   (Australia)

^e PRINCESS ALEXANDRA HOSPITAL   (Australia)

^f ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^g Premion   (Australia)

^h PETER MACCALLUM CANCER CENTRE   (Australia)

ⁱ ROYAL HOBART HOSPITAL   (Australia)

Author keywords

Consensus development conference; Intensity modulated radiotherapy; Practice guidelines; Prostatic neoplasms; Radiotherapy dosage

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; CONSENSUS; EVIDENCE BASED PRACTICE; EXTERNAL BEAM RADIOTHERAPY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MEDICAL SCHOOL; MEDICAL SPECIALIST; MORBIDITY; NEW ZEALAND; ONCOLOGY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; QUALITY CONTROL; RADIATION DOSE; REVIEW; SIMULATION; SINGAPORE; TREATMENT DURATION; TREATMENT PLANNING; WORKSHOP;

AUSTRALIA; HUMANS; IMAGING, THREE-DIMENSIONAL; MALE; NEW ZEALAND; PROSTATIC NEOPLASMS; RADIATION ONCOLOGY; RADIOTHERAPY, INTENSITY-MODULATED; SINGAPORE;

EID: 78650643031     PISSN: 17549477     EISSN: 17549485     Source Type: Journal    
DOI: 10.1111/j.1754-9485.2010.02214.x     Document Type: Review

References (127)

1. AIHW (Australian Institute of Health and Welfare), AACR (Australasian Association of Cancer Registries). 2008. Cancer in Australia: an overview, 2008. Cancer series no. 46. Cat. no. CAN 42. Canberra: AIHW.
2. Ministry of Health. 2010. Cancer: new registrations and deaths 2006. Wellington: Ministry of Health.
3. Widmark A, Klepp O, Solberg A et-al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009; 373: 301-8.
4. Kupelian PA, Langen KM, Willoughby TR, Zeidan OA, Meeks SL. Image-guided radiotherapy for localized prostate cancer: treating a moving target. Semin Radiat Oncol 2008; 18: 58-66.
5. Zelefsky MJ, Fuks Z, Happersett L et-al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 2000; 55: 241-9.
6. Skala M, Berry M, Duchesne G et-al. Australian and New Zealand three-dimensional conformal radiation therapy consensus guidelines for prostate cancer. Aust Radiol 2004; 48: 493-501.
7. D'amico AV, Chen M, Oh-Ung J et-al. Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen era. Int J Radiat Oncol Biol Phys 2002; 54: 436-41.
8. Chung PWM, Haycocks T, Brown T et-al. On-line aSi portal imaging of implanted fiducial markers for the reduction of interfraction error during conformal radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 2004; 60: 329-34.
9. O'Daniel JC, Dong L, Zhang L et-al. Dosimetric comparison of four target alignment methods for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2006; 66: 883-91.
10. Schallenkamp J, Herman M, Kruse JJ, Pisansky TM. Prostate position relative to pelvic bony anatomy based on intraprostatic gold markers and electronic portal imaging. Int J Radiat Oncol Biol Phys 2005; 63: 800-11.
11. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Impact of image guidance on outcomes after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Bio Phys 2008; 70: 1146-50.
12. Dearnaley DP, Khoo VS, Norman AR et-al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999; 353: 267-72.
13. Michalski JM, Winter K, Purdy JA et-al. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose level V. Int J Radiat Oncol Biol Phys 2005; 62: 706-13.
14. Cahlon O, Hunt M, Zelefsky MJ. Intensity modulated radiation therapy: supportive data for prostate cancer. Semin Radiat Oncol 2008; 18: 48-57.
15. De Meerleer GO, Vakaet LA, De Gersem WR, De Wagler C, De Naeyer B, De Neve W. Radiotherapy of prostate cancer with or without intensity modulated beams: a planning comparison. Int J Radiat Oncol Biol Phys 2000; 47: 639-48.
16. Hardcastle N, Davies A, Foo K, Miller A, Metcalfe PE. Rectal dose reduction with IMRT for prostate radiotherapy. J Med Imag Rad Oncol 2010; 54 (3): 235-48.
17. Zelefsky MJ, Levin EJ, Hunt M et-al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity modulated radiotherapy for localised prostate cancer. Int J Radiat Oncol Biol Phys 2008; 70: 1124-9.
18. De Meerleer GO, Fonteyne VH, Vakaet L et-al. Intensity-modulated radiation therapy for prostate cancer: late morbidity and results on biochemical control. Radiother Oncol 2007; 82: 160-6.
19. Jani AB, Su A, Correa D, Gratzle J. Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields. Prostate Cancer Prostatic Dis 2007; 10: 82-6.
20. Al-Mamgani A, Heemsbergen WD, Peeters STH, Lebesque JV. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys 2009; 73 (3): 685-91.
21. Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 2006; 176: 1415-19.
22. Kuban DA, Tucker SL, Starschall G et-al. Long term results of the M.D. Anderson randomized dose escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008; 70: 67-74.
23. Zeitman AL, Bae K, Slater JD et-al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol 2010; 28: 1106-11.
24. Dearnaley DP, Sydes MR, Graham JD et-al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised control trial. Lancet Oncol 2007; 8: 475-87.
25. Beckendorf V, Guerif S, LePrise E et-al. 70-Gy versus (vs) 80-Gy dose escalation Getug 06 French trial for localized prostate cancer: mature results. Int J Radiat Oncol Biol Phys 2008; 72: s96-7.
26. Mamgani AA, van Putten WLJ, Heemsbergen WD et-al. Update of Dutch multicentre dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008; 72: 980-8.
27. Viani GA, Stefano EJ, Alfonso SL. Higher than conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized controlled trials. Int J Radiat Oncol Biol Phys 2009; 74: 1405-18.
28. ICRU 50. Prescribing, recording, and reporting photon beam therapy. Bethesda, MD: International Commission on Radiation Units and Measurements; 1993; ICRU Report 50.
29. ICRU 62. Prescribing, recording, and reporting photon beam therapy (supplement to ICRU Report 50). Bethesda, MD: International Commission on Radiation Units and Measurements; 1999; ICRU Report 62.
30. ICRU 83. Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). Bethesda MD. International Commission no Radiation Units and Measurements; 2010; ICRU Report 83.
31. Guzzo TJ, Vira M, Wang Y et-al. Preoperative parameters, including percent positive biopsy, in predicting seminal vesicle involvement in patients with prostate cancer. J Urol 2006; 175: 518-21.
32. Salomon L, Porcher R, Anastasiadis AG et-al. Introducing a prognostic score for pretherapeutic assessment of seminal vesicle invasion in patients with clinically localized prostate cancer. Radiother Oncol 2003; 67: 313-19.
33. Lieberfarb ME, Schultz D, Whittington R et-al. Using PSA, biopsy Gleason score, clinical stage, and the percentage of positive biopsies to identify optimal candidates for prostate-only radiation therapy. Int J Radiat Oncol Biol Phys 2002; 53: 898-903.
34. Makarov DV, Trock BJ, Humphreys EB et-al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007; 69: 1095-101.
35. Pisansky TM, Blute ML, Suman VJ, Bostwick DG, Earle JD, Zincke H. Correlation of pretherapy prostate cancer characteristics with seminal vesicle invasion in radical prostatectomy specimens. Int J Radiat Oncol Biol Phys 1996; 36: 585-91.
36. Koh H, Kattan MW, Scardino PT et-al. A nomogram to predict seminal vesicle invasion by the extent and location of cancer in systematic biopsy results. J Urol 2003; 170: 1203-8.
37. Gallina A, Chun FK, Briganti A et-al. Development and split-sample validation of a nomogram predicting the probability of seminal vesicle invasion at radical prostatectomy. Eur Urol 2007; 52: 98-105.
38. Kestin L, Goldstein N, Vicini F, Yan D, Korman H, Martinez A. Treatment of prostate cancer with radiotherapy: should the entire seminal vesicles be included in the clinical target volume? Int J Radiat Oncol Biol Phys 2002; 54: 686-97.
39. Davis BJ, Cheville JC, Wilson TM, Slezak JM, Pisansky TM. Histopathologic characterization of seminal vesicle invasion in prostate cancer: implications for radiotherapeutic management. Int J Radiat Oncol Biol Phys 2001; 51: 140-1.
40. Boehmer D, Maingon P, Poortman P et-al. Guidelines for primary radiotherapy of patients with prostate cancer. Radiother Oncol 2006; 79: 259-69.
41. Chao KK, Goldstein NS, Yan D et-al. Clinicopathologic analysis of extracapsular extension in prostate cancer: should the clinical target volume be expanded posterolaterally to account for microscopic extension. Int J Radiat Oncol Biol Phys 2006; 65: 999-1007.
42. Teh BS, Bastasch MD, Wheeler TM et-al. IMRT for prostate cancer: defining target volume based on correlated pathologic volume of disease. Int J Radiat Oncol Biol Phys 2003; 56: 184-191.
43. Sohayda C, Kupelian PA, Levin HS, Klein EA. Extent of extracapsular extension in localized prostate cancer. Urology 2000; 55: 382-6.
44. Lawton CA, DeSilvio M, Roach M et-al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 2007; 69: 646-55.
45. Pommier P, Chaubaud S, Lagrange JL et-al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 2007; 25: 5366-73.
46. van Herk M, Remeijer P, Rasch C, Lebesque JV. The probability of correct target dosage: dose-population histograms for deriving treatment margins in radiotherapy. Int J Radiat Oncol Biol Phys 2000; 47: 1121-35.
47. Fiorino C, Valdagni R, Rancati T, Sanguineti G. Dose-volume effects for normal tissues in external radiotherapy: pelvis. Radiother Oncol 2009; 93: 153-67.
48. Gulliford SL, Foo K, Morgan RC, Aird EG, Bidmead AM et-al. Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 Trial ISRCTN 47772397. Int J Radiat Oncol Biol Phys 2010; 76 (3): 747-54.
49. Michalski JM, Gay H, Jackson A, Tucker SL, Deasey JO. Radiation dosevolume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys 2010; 76: S123-S129.
50. Viswanathan AN, Yorke ED, Marks LB, Eifel PJ, Shipley WU. Radiation dose-volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys 2010; 76: S116-S122.
51. Denham JW, Steigler A, Lamb DS et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005; 6: 841-50.
52. Roach M 3rd, Bae K, Speight J et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long term results of RTOG 8610. J Clin Oncol 2008; 26: 585-91.
53. D'amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008; 299: 289-95.
54. Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-6.
55. Pilepich MV, Winter K, Lawton CA et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61: 1285-90.
56. Horwitz EM, Bae K, Hanks GE et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008; 26: 2497-504.
57. Hanks GE, Pajak TF, Porter A et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003; 21: 3972-8.
58. Bria E, Cuppone F, Giannarelli D et al. Does hormone therapy added to radiotherapy improve outcome in locally advanced prostate cancer. Cancer 2009; 115: 3446-56.
59. Kumar S, Shelley M, Harrison C, Coles B, Wilt T, Mason M. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006; (4): Art. No.:CD006019.
60. Bolla M, de Reijke TM, Van Tienhoven G et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360: 2516-27.
61. Potters L, Gaspar LE, Kavanagh B et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guidelines for image-guided radiation therapy (IGRT). Int J Radiat Oncol Biol Phys 2010; 76: 319-25.
62. Whitton A, Warde P, Sharpe M et al. Organisational standards for the delivery of intensity-modulated radiation therapy in Ontario. Clin Oncol (R Coll Radiol) 2009; 21: 192-203.
63. Ezzell GA, Galvin JM, Low D et al. Guidance document on delivery, treatment planning, and clinical implementation of IMRT: report of the IMRT Subcommittee of the AAPM Radiation Therapy Committee. Med Phys 2003; 30: 2089-115.
64. Galvin JM, Ezzell G, Eisbrauch A et al. Implementing IMRT in clinical practice: a joint document of the American Society for Therapeutic Radiology and Oncology and the American Association of Physicists in Medicine. Int J Radiat Oncol Biol Phys 2004; 58: 1616-34.
65. Storey MR, Pollack A, Zagars G, Smith L, Antolak J, Rosen I. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 2000; 48: 635-42.
66. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organi-zation for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341-6.
67. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-30.
68. Barry MJ, Fowler FJ Jr, O'Leary MP et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148: 1549-57.
69. Comprehensive cancer network categories of evidence and consensus. Updated January 2008. [Cited 7 Dec 2009.] Available from URL.
70. Smith S, Catalona WJ. The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 1994; 152: 1732-6.
71. Berney DM, Fisher G, Kattan MW et al. Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading. BJU Int 2007; 100: 1240-4.
72. Chism DB, Hanlon AL, Troncoso P, Al-Saleem T, Horwitz EM, Pollack A. The Gleason score shift: score four and seven years ago. Int J Radiat Oncol Biol Phys 2003; 56: 1241-7.
73. D'amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy or interstitial radiation therapy for clinically localised prostate carcinoma. JAMA 1998; 280: 969-74.
74. D'amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005; 294: 440-7.
75. D'amico AV, Renshaw AA, Cote K et al. Impact of the percentage of positive prostate cores on prostate cancer specific mortality for patients with low or favourable-intermediate risk disease. J Clin Oncol 2004; 22: 3726-32.
76. D'amico AV, Keshaviah A, Manola J et al. Clinical utility of the percentage of positive prostate biopsies in predicting prostate cancer-specific and overall survival after radiotherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2002; 53: 581-7.
77. Kestin LL, Goldstein NS, Vicini FA, Martinez AA. Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy. J Urol 2002; 168: 1994-9.
78. Wong WW, Schild SE, Vora SA, Halyard MY. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004; 60: 24-9.
79. Stark JR, Perner S, Stampfer MJ et al. Gleason score and lethal prostate cancer: does 3+4 = 4+3? J Clin Oncol 2009; 27: 3459-64.
80. Burdick MJ, Reddy CA, Ulchaker J et al. Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer. Int J Radiat Oncol Biol Phys 2009; 73: 1439-45.
81. Beard C, Schultz D, Loffredo M et al. Perineural invasion associated with increased cancer-specific mortality after external beam radiation therapy for men with low- and intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys 2006; 66: 403-7.
82. Williams SG, Buyyounouski MK, Pickles T et al. Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3264 men: statistical significance without predictive performance. Int J Radiat Oncol Biol Phys 2008; 70: 1169-75.
83. Pinsky PF, Andriole G, Crawford ED et al. Prostate-specific antigen velocity and prostate cancer Gleason grade and stage. Cancer 2007; 109: 1689-95.
84. Litzenberg D, Dawson LA, Sandler H et al. Daily prostate targeting using implanted radiopaque markers. Int J Radiat Oncol Biol Phys 2002; 52: 699-703.
85. Boda-Heggemann J, Kohler FM, Kupper B et al. Accuracy of ultrasound-based (BAT) prostate-repositioning: a three-dimensional on-line fiducial-based assessment with cone-beam computed tomography. Int J Radiat Oncol Biol Phys 2008; 70: 1247-55.
86. Murphy MJ, Balter J, Balter S et al. The management of imaging dose during image-guided radiotherapy: report of the AAPM Task Group 75. Med Phys 2007; 34: 4041-63.
87. National Research Council. Health Risks from Exposure to Low Levels of Ionizing Radiation. BEIR VII Phase 2.National Academies Press, Washington, DC, 2006.
88. Brenner DJ, Doll R, Goodhead DT et al. Cancer risks attributable to low doses of ionizing radiation: assessing what we really know. Proc Natl Acad Sci U S A 2003; 100: 13761-6.
89. Zelefsky MJ, Hunt MA, Fuks Z et al. Long-term distant metastases-free survival and cause-specific survival outcomes after high dose conformal radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2006; 66: S9.
90. Hanks GE, Hanlon AL, Epstein B, Horwitz EM. Dose-response in prostate cancer with 8-12 years' follow-up. Int J Radiat Oncol Biol Phys 2002; 54: 427-35.
91. Morgan PB, Hanlon AL, Horwitz EM, Buyyounouski MK, Uzzo RG, Pollack A. Radiation dose and late failures in prostate cancer. Int J Radiat Oncol Biol Phys 2007; 67: 1074-81.
92. Valicenti R, Lu J, Pilepich M, Asbell S, Grignon D. Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials. J Clin Oncol 2000; 18: 2740-9.
93. Syndikus I, Morgan RC, Sydes MR, Graham JD, Dearnaley DP. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial. Int J Radiat Oncol Biol Phys 2010; 77: 773-83.
94. Das IJ, Cheng C, Chopra KL, Mitra Rk, Srivastava SP, Glatstein E. Intensity-modulated radiation therapy dose prescription, recording, and delivery: patterns of variability among institutions and treatment planning systems. J Natl Cancer Inst 2008; 100: 300-7.
95. Holmes T, Das R, Low D et al. American Society of Radiation Oncology recommendations for documenting intensity-modulated radiation therapy treatments. Int J Radiat Oncol Biol Phys 2009; 74: 1311-18.
96. Malone S, Szanto J, Perry G et al. A prospective comparison of three systems of patient immobilization for prostate radiotherapy. Int J Radiat Oncol Biol Phys 2000; 48: 657-65.
97. Stasi M, Munoz F, Pasquino M et al. Emptying the rectum before treatment delivery limits the variations of rectal dose - volume parameters during 3DCRT of prostate cancer. Radiother Oncol 2006; 80: 363-70.
98. Fiorino C, Di Muzio N, Broggi S et al. Evidence of limited motion of the prostate by carefully emptying the rectum as assessed by daily MVCT image guidance with helical tomotherapy. Int J Radiat Oncol Biol Phys 2008; 71: 611-17.
99. Smitsmans MHP, Pos FJ, de Bois J et al. The influence of a dietary protocol on cone beam CT-guided radiotherapy for prostate cancer patients. Int J Radiat Oncol Biol Phys 2008; 71: 1279-86.
100. Nichol AM, Warde PR, Lockwood GA et al. A cinematic magnetic resonance imaging study of milk of magnesia laxative and an antiflatulent diet to reduce intrafraction prostate motion. Int J Radiat Oncol Biol Phys 2010; 77: 1072-8.
101. Shinohara K, Roach M III. Technique for implantation of fiducial markers in the prostate. Urology 2008; 71: 196-200.
102. Rasch C, Barillot I, Remeijer P, Touw A, van Herk M, Lebesque JV. Definition of the prostate in CT and MRI: a multi-observer study. J Radiat Oncol Biol Phys 1999; 43: 57-66.
103. Kagawa K, Lee WR, Schultheiss TE, Hunt MA, Shaer AH, Hanks GE. Initial clinical assessment of CT-MRI image fusion software in localisation of the prostate for 3D conformal radiation therapy. Int J Radiat Oncol Biol Phys 1997; 38: 319-25.
104. Steenbakers RJ, Deurloo KE, Nowak PJ, Lebesque JV, van Herk M, Rasch CR. Reduction of dose delivered to the rectum and bulb of the penis using MRI delineation for radiotherapy of the prostate. Int J Radiat Oncol Biol Phys 2003; 57: 1269-79.
105. Villeirs GM, Verstraete KL, De Neve WJ, De Meerleer GO. Magnetic resonance imaging anatomy of the prostate and periprostatic area: a guide for radiotherapists. Radiother Oncol 2005; 76: 99-106.
106. McLoughlin PW, Evans C, Feng M, Narayana V. Radiographic and anatomic basis for prostate contouring errors and methods to improve prostate contouring accuracy. Int J Radiat Oncol Biol Phys 2010; 76: 369-78.
107. Rosewall T, Kong V, Vesprini D et al. Prostate delineation using CT and MRI for radiotherapy patients with bilateral hip prostheses. Radiother Oncol 2009; 90: 325-30.
108. Parker CC, Damyanovich A, Haycocks T, Haider M, Bayley A, Catton C. Magnetic resonance imaging in the radiation treatment planning of localized prostate cancer using intra-prostatic fiducial markers for computed tomography co-registration. Radiother Oncol 2003; 66: 217-24.
109. Cagiannos I, Karakiewicz P, Eastham JA et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 2003; 170: 1798-803.
110. Lawton CA, Michalski J, El-Naqa I et al. RTOG GU radiation oncology specialists reach consensus on pelvic lymph nose volumes for high risk prostate cancer. Int J Radiat Oncol Biol Phys 2009; 74: 383-7.
111. Greer PB, Dahl K, Ebert MA, Wratten C, White M, Denham JW. Comparison of prostate set-up accuracy and margins with off-line bony anatomy corrections and online implanted fiducial-based corrections. J Med Imaging Radiat Oncol 2008; 52 (5): 511-16.
112. Verellen D, De Ridder M, Tournel K et al. An overview of volumetric imaging technologies and their quality assurance for IGRT. Acta Oncol 2008; 47: 1271-8.
113. Boersma LJ, van den Brink M, Bruce AM et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys 1998; 41: 83-92.
114. Harsolia A, Vargas C, Yan D et al. Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive 3Dconformal RT: dose-volume analysis of a Phase III dose-escalation study. Int J Radiat Oncol Biol Phys 2007; 69: 1100-9.
115. Heemsbergen WD, Al-Mamgani A, Witte MG, van Herk M, Pos FJ, Lebesque JV. Urinary obstruction in prostate cancer patients from the Dutch trial (68 Gy vs 78 Gy): relationships with local dose, acute effects, and baseline characteristics. Int J Radiat Oncol Biol Phys 2010; 78: 19-25.
116. Martinez AA, Demanes DJ, Galalae R et al. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Int J Radiat Oncol Bio Phys 2005; 62: 1322-31.
117. Kupelian PA, Mohan DS, Lyons J, Klein EA, Reddy CA. Higher than standard radiation doses (> or = 72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 2000; 46: 567-74.
118. Trans-Tasman Radiation Oncology Group. Randomised androgen deprivation and radiotherapy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [Cited 15 Jan 2010.] Available from URL: NLM Identifier: NCT00193856.
119. Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006; 175: 136-9.
120. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation therapy for prostate cancer. N Engl J Med 2005; 352: 154-64.
121. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 2009; 181: 1998-2006.
122. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007; 99: 1516-24.
123. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448-56.
124. D'amico AV, Denham JW, Crook J et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007; 25: 2420-5.
125. Saigal CS, Gore JL, Krupski TL et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007; 110: 1493-500.
126. Holmes-Walker DJ, Woo H, Gurney H, Do VT, Chipps DR. Maintaining bone health in patients with prostate cancer. Med J Aust 2006; 184: 176-9.
127. Fraass B, Doppke K, Hunt M et al. American Association of Physicists in Medicine Radiation Therapy Committee Task Group 53: quality assurance for clinical radiotherapy treatment planning. Med Phys 1998; 25: 1773-829.